2-(3,4-difluorophenyl)-5-methyl-2H-pyrazol-3-ylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3,4-difluorophenyl)-5-methyl-2H-pyrazol-3-ylamine
• 英文别名: 2-(3,4-Difluorophenyl)-5-methylpyrazol-3-amine；2-(3,4-difluorophenyl)-5-methylpyrazol-3-amine
• 化学式: C₁₀H₉F₂N₃
• 分子量: 209.198
• InChiKey: DPWINUYQYPCDFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氨基巴豆腈 、 3,4-二氟苯肼HC 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 生成 2-(3,4-difluorophenyl)-5-methyl-2H-pyrazol-3-ylamine
  参考文献：
  名称：

  [EN] N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE
  [FR] PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES N-SULFONYLÉS ET LEUR PROCÉDÉ D'UTILISATION

  摘要：

  本发明提供了一种具有以下结构的化合物（I），其中R1、R2、R3、R4、R5和R6具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个具有结构（I）的化合物组成的药物组合物。

  公开号：

  WO2017060874A1

文献信息

• SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170101406A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式（I）的化合物 其中R 1 ，R 2 ，R 3 和R 4 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式（I）的化合物组成的药物组合物。
• N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
  申请人：AbbVie S.à.r.l.

  公开号：US10259810B2

  公开（公告）日：2019-04-16

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式 (I) 的化合物 其中 R1、R2、R3、R4、R5 和 R6 具有说明书中定义的任一值，及其药学上可接受的盐，可作为治疗由 CFTR 介导和调节的疾病和病症的药物，包括囊性纤维化、Sjögren 综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一种或多种式（I）化合物组成的药物组合物。
• N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
  申请人：AbbVie S.à.r.l.

  公开号：US10647717B2

  公开（公告）日：2020-05-12

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式 (I) 的化合物 其中 R1、R2、R3、R4、R5 和 R6 具有说明书中定义的任一值，及其药学上可接受的盐，可作为治疗由 CFTR 介导和调节的疾病和病症的药物，包括囊性纤维化、Sjögren 综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一种或多种式（I）化合物组成的药物组合物。
• N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE
  申请人：AbbVie Overseas S.à r.l.

  公开号：EP3359541B1

  公开（公告）日：2020-08-05
• N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE
  申请人：AbbVie S.à.r.l

  公开号：US20170101405A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).